Table 1.

Study characteristics including in our meta-analysis

Study	Trial name	Publication year	Design	Country	Treatment group	Control group
Dimopoulos et al.	CANDOR trial	2020	Phase 3 randomized control trial	North America, Europe, Australia, and Asia	Carfilzomib, dexamethasone, and daratumumab	Carfilzomib, dexamethasone
Spencer et al.	CASTOR trial	2018	Phase 3 randomized control trial	Australia	Daratumumab plus bortezomib and dexamethasone	bortezomib and dexamethasone
Dimopoulos, et al.	POLLUX trial	2018	Phase 3 randomized control trial	Canada, North America, and Australia	Daratumumab plus lenalidomide and dexamethasone	lenalidomide and dexamethasone